乳腺癌术后辅助性全身治疗
被引量：1
Systemic Adjuvant Therapy for Breast Cancer after Surgery
摘要
全文综述了最近几年乳腺癌术后辅助性全身治疗方面的进展及热点问题。
出处
《中国肿瘤》
CAS
2001年第11期653-654,共2页
China Cancer
参考文献9
-
1Early Breast Cancer Trialists Collaboratie Group. Tamoxifen for early breast cancer: An overview of the randomised trials[J]. Lancet , 1998, 351: 1451-1467.
-
2Aebi S, Gelber S, Castiglione-gertsch M, et al . Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? [J] . Lancet, 2000, 355:1869-1874.
-
3Davidson NE. Hormonal ablation [ A ]. NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer[ C ]. Bethesda: National Institutes of Health, 2000.63-66.
-
4Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, et al. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study [J]. J Clin Endocrine Metab, 2000, 85: 645-651.
-
5Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer [J] .J Natl Cancer Inst, 1997, 89:1673-1682.
-
6Handerson IC, Berry D, Demetri G, et al. Improved disease-free (DFS)and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of Doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC)[J]. Proc Am Soc Clin Oncol, 1998, 17: 101a(abstr 390A).
-
7Bonadonna G, Zambette M, Valagussa P. Sequential or alternating doxorubicin and CMF refimens in breast cancer with more than three positive nodes: Ten-year results[ J ]. JAMA, 1995,273: 542-547.
-
8Piccart MJ, Goldhirsch A.For the Breast International Group: An overview of recent and ongoing adjuvant clinical trials for brest cancer (2ed) [ R ]. Brussels: Breast International Group, 2000.
-
9Thor Ad, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer[J] .J Natl Cancer Inst, 1998, 90: 1346-1360.
同被引文献10
-
1Javier R Javier C Oscar FH et al.泰索帝和诺维本联合化疗方案作为转移性乳腺癌干细胞支持下的大剂量化疗失败后的补救治疗方案临床n期试验研究[J].ASCO,2002,:2072-2072.
-
2JoseIM AlfredoM SerafinM etal.转移性乳腺癌中两周一次的泰索帝和诺维本联合化疗作为一线治疗方案的临床n期试验研究[J].ASCO,2002,:2014-2014.
-
3Marwane G Fadi F Joseph K et al.诺维本与希罗达联合应用作为一线治疗方案在转移性乳腺癌中作用[J].ASCO,2002,:1978-1978.
-
4Serafin M Ignacio M Jose AMN et al.表-阿霉素/诺维本序贯联合每周一次泰索帝的化疗方案一线治疗转移性乳腺癌的临床n期试验研究[J].ASCO,2002,:2041-2041.
-
5冷传春,梅家转,施恩,柏敏霜.去甲长春花碱联合阿霉素治疗28例转移性乳腺癌疗效观察[J].中国肿瘤临床,2001,28(2):154-155. 被引量：2
-
6江泽飞,宋三泰.乳腺癌辅助内分泌治疗若干问题的新认识[J].中华肿瘤杂志,2001,23(1):81-82. 被引量：28
-
7田嘉玲,宫超,黄克楠,刘伯英.诺维苯联合化疗治疗晚期复发乳腺癌10例临床观察[J].中国肿瘤临床,2001,28(4):311-312. 被引量：2
-
8徐兵河.乳腺癌药物治疗的现状与展望[J].肿瘤学杂志,2001,7(2):65-68. 被引量：1
-
9汪安兰.乳腺癌的内科治疗[J].中国肿瘤,2001,10(11):660-662. 被引量：9
-
10冯奉仪,周爱萍.剂量强度和高剂量化疗在乳腺癌中的应用[J].中华肿瘤杂志,2002,24(2):200-202. 被引量：5
-
1徐文怀,王振军.甲状腺癌的辅助治疗[J].中国实用外科杂志,1995,15(2):81-82. 被引量：3
-
2谢衡生,王仁顺,莫克俭.晚期前列腺癌的内分泌治疗[J].中国医师杂志,2002,4(11):1278-1279.
-
3Santen RJ,王德全,任建民.乳腺癌的内分泌疗法[J].国外医学（肿瘤学分册）,1991,18(2):101-103.
-
4李伟,张金池,陶可胜.胃癌组织中雌激素受体的表达及其临床意义[J].泰山医学院学报,1994,15(3):168-170. 被引量：1
-
5郭先予,陈松旺,王自法.乳腺癌的内分泌疗法[J].现代肿瘤医学,1995,3(1):10-11.
-
6郑炳初.乳腺癌的内分泌治疗[J].浙江肿瘤,1992(3):51-55.
-
7出村孝义.前列腺癌内分泌疗法的适应证及其限度[J].日本医学介绍,1999,20(3):117-118.
-
8Rao BR,王德全,任建民.卵巢上皮癌与内分泌[J].国外医学（肿瘤学分册）,1992,19(1):45-47. 被引量：1
-
9李玉民,魏育才.胰头癌的外科治疗进展[J].国际外科学杂志,2015,42(6):366-369.
-
10钟元培.乳腺癌内分泌治疗[J].重庆医学,1995,24(4):210-211.
